Incumbent-intelligence read on this vehicle: who holds it, how the money has moved, and where the option runway opens the next recompete.
UNCLASSIFIED // COMPANY PROPRIETARY
Prepared August 1, 2026. Information available as of August 1, 2026. Built entirely from public federal records. All portions of this product are marked (U). Analysis is derived from public records, not verified fact; verify independently before relying on it. Handle as company proprietary.
Evidence Markings
DETERMINED: an observed fact from the public record.
INFERRED: an analytic judgment, carrying a stated confidence level.
MUST-CHECK: an intelligence gap, written as an action item for the capture team.
Confidence Scale
High: corroborated by multiple independent public sources; minimal inference.
Moderate: credibly sourced but not fully corroborated, or partial inference.
Low: fragmented, uncorroborated, or assumption-heavy.
Public preview: the holder roster and vehicle ceiling are free. A free account unlocks more; subscriptions are coming soon.Sign up freePricing
◎ Contract Vehicle SITREP
Analysis derived from public records, not verified fact. Verify independently before relying on it.
36F79718D0310
Incumbent-intelligence read on this vehicle: who holds it, how the money has moved, and where the option runway opens the next recompete.
Multi-award vehicle (MAC / GWAC / Schedule) (FSS) · Multiple award · Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797)
$23.0B ceiling54 holdersNAICS 325412
§1
Bottom Line Up Front
▪What this is. 36F79718D0310 is a multi-award vehicle (mac / gwac / schedule) (FSS) issued by Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797), solicitation M5-Q50A-03-R7, a multiple award vehicle with a combined ceiling of $23.0B, held by 54 primes on the public record.
▪The money. Funded totals against the $23.0B ceiling, split by prime, are a subscription read; the holder roster is on the public record below.
▪Recompete timing. No period-of-performance end is on record for this vehicle; recompete timing is not determined.
▪The read. For a challenger: the holder roster below is the field to beat, and the option runway sets the earliest realistic entry point. For an incumbent: defend the funded share and the option ladder now, and watch for deobligations or thinning competition as an early signal of a scope change.
§2
Entity Baseline
What this vehicle is and its scale, from the public contract record. Raw identifiers live here and in Sourcing; the body refers to the vehicle and its holders by name.
Vehicle
36F79718D0310
Type
Multi-award vehicle (MAC / GWAC / Schedule) (FSS)
Award structure
Multiple award
Awarding agency / office
Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797)
Combined ceiling
$23.0B
Funded to date
available with subscription
Period through
n/a
Base solicitation
M5-Q50A-03-R7
NAICS / PSC
325412 · PSC 6505
§3
Incumbent Baseline · Prime Roster
Every prime holder on the vehicle, from public contract award records. These are the incumbents a challenger displaces and the field most likely to defend.
🔒 Funded share, task orders, and corporate history
Funded position by prime, the fiscal-year obligation curve, order-level detail with options and deobligations, novation history, competition intensity, teaming, and how this buying office competes the category overall. Paid plans read the contract action records.
Who actually places orders under this vehicle, from public contract award records.
Agencies
No agencies with recorded orders under this vehicle yet.
Offices
No offices with recorded orders under this vehicle yet.
§6
Key Analytic Assessments
DETERMINEDHigh confidence
The incumbent roster is on the public record. This vehicle is a 54-holder multiple-award family with a combined ceiling of $23.0B, held by BRISTOL-MYERS SQUIBB COMPANY, MERCK SHARP & DOHME LLC, ELI LILLY AND COMPANY, IPSEN BIOPHARMACEUTICALS INC, UPSHER-SMITH LABORATORIES, LLC, ALKERMES, INC., NEPHRON PHARMACEUTICALS CORPORATION, FOCUS HEALTH GROUP, INC., GALDERMA LABORATORIES, L.P., GE HEALTHCARE INC, ACTELION PHARMACEUTICALS US, INC., KOWA PHARMACEUTICALS AMERICA INC, CONCORDIA PHARMACEUTICALS INC., SHIONOGI INC, BTG INTERNATIONAL INC, WOCKHARDT USA LLC, ALVOGEN, INC., PACIRA PHARMACEUTICALS, INC., MITSUBISHI TANABE PHARMA AMERICA, INC., DEPUY SYNTHES SALES INC, ICU MEDICAL SALES, INC., ESPERO PHARMACEUTICALS, INC., VIRTUS PHARMACEUTICALS, LLC, KYOWA KIRIN, INC., MELINTA THERAPEUTICS, LLC, HELSINN THERAPEUTICS (U.S.), INC., HERON THERAPEUTICS, INC., LA JOLLA PHARMACEUTICAL COMPANY, ACHAOGEN, INC., MEDEXUS PHARMA INC, INTERSECT ENT, INC., CERA PRODUCTS, INC., ASCEND LABORATORIES LLC, CORCEPT THERAPEUTICS INCORPORATED, MANNKIND CORPORATION, NORDIC PHARMA, INC., OTONOMY, INC., QUINN PHARMACEUTICALS, LLC, BIODELIVERY SCIENCES INTERNATIONAL, INC, GREER LABORATORIES, INC., ONY BIOTECH INC, AMRYT PHARMACEUTICALS INC., VYERA PHARMACEUTICALS, LLC, AERIE PHARMACEUTICALS INC, ARALEZ PHARMACEUTICALS US INC., GENERICUS, INC., STI PHARMA LLC, NIELSEN BIOSCIENCES INC, OPKO PHARMACEUTICALS LLC, TESARO, INC., EPI HEALTH, LLC, GLENMARK PHARMACEUTICALS INC., USA, NAPO PHARMACEUTICALS INC, GEMINI LABORATORIES LLC.
MUST-CHECKintelligence gap
Successor vehicle structure. Whether this vehicle re-competes as a standalone follow-on or the requirement migrates onto a different GWAC or Schedule path is not established on the public record.
§7
Intelligence Gaps & Outlook
What this SITREP could not determine from the public record, consolidated. Each is an action for the capture team.
▸Exact option end and extensions. the option ladder shown reflects exercised actions on record; the contractual final option end date and any bilateral extensions are a solicitation-document pull, not a public contract-action fact.
▸Successor vehicle structure. whether this scope re-competes as a standalone follow-on, a new GWAC lane, or an existing Schedule path is unposted until the buying office publishes it.
▸Past-performance attribution on novated seats. how a recompete evaluation would score incumbency acquired by novation is an RFP and legal question, not a settled public-record fact.
▸Teaming beyond the reported floor. first-tier subcontract reporting is thresholded and under-reported; mentor-protege and joint-venture ties are not in these records.
▸Current SAM size and status of every holder. business size and socioeconomic standing reflect each holder's registration on file; confirm the current size rep for any specific target NAICS before relying on set-aside eligibility.
INFERRED
§8
Sourcing
All findings derive from public federal records, as of Sat Aug 01. Raw identifiers live here and in the Entity Baseline.
Federal contract award records (FPDS / USASpending), vehicle 36F79718D0310, contract ID CONT_IDV_36F79718D0310_3600, Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797), NAICS 325412, PSC 6505, combined ceiling $23.0B.
◎ CONTRACT VEHICLE SITREP // UNCLASSIFIED // COMPANY PROPRIETARY
Investigate|Radar|Illustrative intelligence from public data; supports, does not replace, your capture decision. The live record on SAM and USASpending always governs.
DETERMINEDHigh confidence54 prime holder(s) on the vehicle
MUST-CHECKintelligence gap
Teaming coverage is partial. First-tier subcontract reporting is required only above a dollar threshold and many primes under-report, so any teaming picture is a floor, not the full bench.
Moderate confidence
outlook
Short to medium term: the prime roster above defends its position on the vehicle, with the option runway setting the near-term recompete clock. The watch items that move this read are any RFP or successor-vehicle notice under this office and NAICS, new teaming that signals a bid, and a change in the funded-share leader.
V797D70237
MKFCR1R78GD3
; CONCORDIA PHARMACEUTICALS INC. (contract V797D50516, UEI NNMGM5SLUJM3, ceiling $74M)